General MedicationsOPHTHALMICStandard
IHEEZO
CHLOROPROCAINE HYDROCHLORIDE
Standard Dose
3%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview IHEEZO is listed in Drugs@FDA under application 216227 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient CHLOROPROCAINE HYDROCHLORIDE Form and strength GEL;OPHTHALMIC - 3% Sponsor HARROW EYE Submission history Latest submission status date: 2022-09-27 00:00:00.
Structured Monograph
Clinical summary
Approval overview IHEEZO is listed in Drugs@FDA under application 216227 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient CHLOROPROCAINE HYDROCHLORIDE Form and strength GEL;OPHTHALMIC - 3% Sponsor HARROW EYE Submission history Latest submission status date: 2022-09-27 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.